Scarica l'app Stockscreener
5.56
3.93%
0.21
Dopo l'orario di chiusura:
5.56
Precedente Chiudi:
$5.35
Aprire:
$5.32
Volume 24 ore:
869.28K
Relative Volume:
1.45
Capitalizzazione di mercato:
$218.11M
Reddito:
$425.17M
Utile/perdita netta:
$-92.21M
Rapporto P/E:
556.00
EPS:
0.01
Flusso di cassa netto:
$-67.42M
1 W Prestazione:
+5.90%
1M Prestazione:
+11.87%
6M Prestazione:
-50.75%
1 anno Prestazione:
-65.40%
Intervallo 1D:
$5.22
$5.66
Intervallo di 1 settimana:
$5.10
$5.71
Portata 52W:
$4.382
$22.64
Nevro Corp Stock (NVRO) Company Profile
Nome
Nevro Corp
Settore
Industria
Telefono
650-251-0005
Indirizzo
1800 BRIDGE PARKWAY, REDWOOD CITY, CA
Nevro Corp Stock (NVRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-01-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-12-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-07-19 | Iniziato | Robert W. Baird | Neutral |
| 2023-05-31 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-15 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-04-14 | Iniziato | Mizuho | Neutral |
| 2023-01-17 | Downgrade | Citigroup | Buy → Neutral |
| 2023-01-06 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2022-12-20 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2022-12-12 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Underperform |
| 2022-05-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-04-13 | Ripresa | Truist | Hold |
| 2022-04-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Underperform |
| 2022-01-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-11-09 | Downgrade | Truist | Buy → Hold |
| 2021-08-05 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-08-05 | Downgrade | Citigroup | Buy → Neutral |
| 2021-08-05 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-08-05 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2021-08-05 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-07-09 | Downgrade | Redburn | Buy → Neutral |
| 2021-07-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-02-02 | Iniziato | Piper Sandler | Overweight |
| 2020-10-23 | Iniziato | Guggenheim | Buy |
| 2020-09-02 | Iniziato | Robert W. Baird | Outperform |
| 2020-06-08 | Aggiornamento | UBS | Sell → Neutral |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-01-08 | Iniziato | SunTrust | Buy |
| 2020-01-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2019-11-07 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-10-22 | Iniziato | Oppenheimer | Perform |
| 2019-03-20 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-03-20 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2018-11-28 | Iniziato | UBS | Sell |
| 2018-11-07 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-11-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-06 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2018-10-19 | Downgrade | Goldman | Neutral → Sell |
| 2018-07-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-05-08 | Reiterato | Canaccord Genuity | Buy |
| 2018-05-08 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2018-05-08 | Downgrade | Wells Fargo | Outperform → Market Perform |
Mostra tutto
Nevro Corp Borsa (NVRO) Ultime notizie
Nevro (NVRO) to Release Earnings on Monday - MarketBeat
Nevro (FRA:1N7) Profitability Rank : 1 (As of Jun. 2024) - GuruFocus.com
Nevro (NYSE:NVRO) Upgraded to Hold at StockNews.com - MarketBeat
Assenagon Asset Management S.A. Increases Position in Nevro Corp. (NYSE:NVRO) - MarketBeat
New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy - PR Newswire
Nevro Corp. (NYSE:NVRO) Receives Average Rating of "Reduce" from Analysts - MarketBeat
President & CEO Thornal Kevin R covered exercise/tax liability with 6,063 shares, decreasing direct ownership by 2% to 249,847 units (SEC Form 4) - Quantisnow
Chronic Pain Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | AstraZeneca, Regenacy Pharma, Nevro Corp., Erchonia Corporation - The Globe and Mail
StockNews.com Upgrades Nevro (NYSE:NVRO) to Hold - MarketBeat
Trading (NVRO) With Integrated Risk Controls - Stock Traders Daily
Nevro announces new inducement grants - Medical Buyer
StockNews.com Lowers Nevro (NYSE:NVRO) to Sell - MarketBeat
Nevro shares target cut by Baird, retains neutral stance - Investing.com Australia
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - Marketscreener.com
Nevro Corp (NVRO) PT Lowered to $5 at Baird - StreetInsider.com
Nevro Corp. (NYSE:NVRO) Shares Sold by Dimensional Fund Advisors LP - MarketBeat
Nevro to Report Third-Quarter 2024 Financial Results and Host Earnings Conference Call on November 11, 2024 - BioSpace
Millennium Management LLC Increases Holdings in Nevro Corp. (NYSE:NVRO) - MarketBeat
Here's Why You Should Retain Nevro (NVRO) Stock for Now - MSN
SVP, Corp Dev and CLO Rashid Kashif covered exercise/tax liability with 479 shares, decreasing direct ownership by 0.30% to 161,352 units (SEC Form 4) - Quantisnow
Nevro obtains FDA approval for AI-based spinal cord stimulation system - MSN
Nevro Corp. (NYSE:NVRO) Shares Purchased by Point72 Asset Management L.P. - MarketBeat
Nevro Corp. (NYSE:NVRO) Receives $10.55 Consensus Price Target from Brokerages - MarketBeat
Nevro Corp. (NYSE:NVRO) Shares Sold by Cubist Systematic Strategies LLC - MarketBeat
Breaking Down Nevro: 10 Analysts Share Their Views - Benzinga
Nevro (NYSE:NVRO) PT Lowered to $6.00 at Citigroup - MarketBeat
Nevro Corp.'s SWOT analysis: stock faces headwinds amid SCS market challenges - Investing.com India
Nevro Corp.'s SWOT analysis: stock faces headwinds amid SCS market challenges By Investing.com - Investing.com South Africa
Where are the Opportunities in (NVRO) - Stock Traders Daily
Here's Why you Should Retain Nevro Stock in Your Portfolio Now - Yahoo Finance
Nevro Corp. (NYSE:NVRO) Shares Sold by Fred Alger Management LLC - MarketBeat
NVRO Stock May Gain on the FDA Approval of Its HFX AdaptivAI Platform - Yahoo Finance
Nevro wins FDA nod for AI-driven spinal cord stimulation tech - Mass Device
Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation - PR Newswire
Global Electrotherapy System Research Report 2024: A $1.65 Billion Market by 2030 - GlobeNewswire Inc.
Nevro Corp. (NYSE:NVRO) Stake Raised by Acadian Asset Management LLC - MarketBeat
Vanguard Group Inc's Strategic Reduction in Nevro Corp Holdings - Yahoo Finance
Nevro Corp. (NYSE:NVRO) Given Consensus Recommendation of "Reduce" by Analysts - MarketBeat
Nevro (NYSE:NVRO) Share Price Passes Below 50-Day Moving Average of $7.62 - MarketBeat
Microelectronic Medical Implants Market Report 2024-2029, with Profiles of Leading Players, including Abbott, Biotronik, Cochlear, LivaNova, Medtronic, Neuropace and Nevro - Yahoo Finance UK
(NVRO) Trading Report - Stock Traders Daily
SVP, Corp Dev and CLO Rashid Kashif covered exercise/tax liability with 817 shares, decreasing direct ownership by 0.50% to 163,590 units (SEC Form 4) - Quantisnow
Nevro to Present at Wells Fargo 2024 Healthcare Conference - The Malaysian Reserve
Nevro (NYSE:NVRO) Lowered to "Sell" at StockNews.com - MarketBeat
Assenagon Asset Management S.A. Has $6.13 Million Position in Nevro Corp. (NYSE:NVRO) - MarketBeat
Nathan B Pliam Net Worth (2024) - GuruFocus.com
Nevro Corp. (NYSE:NVRO) Given Average Recommendation of "Reduce" by Analysts - MarketBeat
Nevro Corp. (NYSE:NVRO) Given Average Rating of “Reduce” by Brokerages - Defense World
Nevro Corp Azioni (NVRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.47%
1.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):